TheAnswerPage

JANUARY 9, 2022

Has CBDV been evaluated as an anti-seizure medication in clinical trials? Yes, GW Pharmaceuticals (the makers of Epidiolex) had trialed CBDV in adult epilepsy, but the study did not meet its primary endpoint of seizure reduction. That trial did not continue.

Clinical Trials

Cannabis Law Report

SEPTEMBER 13, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021. in the blood. About MyMD Pharmaceuticals, Inc.

Clinical Trials

Cannabis Law Report

DECEMBER 20, 2021

First Patient Expected to be Enrolled by Q2 of 2022. Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing product candidates for pain management, CNS disorders and anti-viral indications, signed a clinical trial agreement with Altasciences Company, Inc., BERWYN, Pa.–(BUSINESS About Altasciences.

Clinical Trials

TheAnswerPage

MAY 25, 2022

The results of recent clinical trials indicate that Cannabidiol (CBD) reduces seizures among patients with refractory epilepsies of various etiologies. Most of these clinical studies report efficacy over short time periods (. The long-term efficacy of cannabidiol in the treatment of refractory epilepsy.

Clinical Trials

Veriheal

MARCH 23, 2023

The report states that the revision is an essential move for ensuring the legal use of cannabis-derived epilepsy drug Epidiolex , which is currently being reviewed as part of a series of clinical trials in Japan. Japan’s latest Cannabis Control Law revisions would apply to pharmaceutical-grade medicinal cannabis products.

Legalization

Cannabis Law Report

JANUARY 24, 2022

DUBLIN–(BUSINESS WIRE)–The “North America Legal Cannabis Market Size, Share & Trends Analysis Report by Sources (Marijuana, Hemp), by Derivatives (CBD, THC), by End Use (Medical, Recreational), and Segment Forecasts, 2022-2028” report has been added to ResearchAndMarkets.com’s offering. from 2022 to 2028.

Legalization

Cannabis Law Report

DECEMBER 28, 2021

We recently announced that we anticipate commencing our initial human trial for Epoladerm™ in the second quarter of 2022. We added VRP324 which is an intranasally delivered cannabidiol (‘CBD’) formulation for the management of epilepsy in adults and children. Virpax initially focused strictly on pain product candidates.

Pharmaceutical

Cannabis Law Report

NOVEMBER 16, 2021

Believed to be the only IND application ever cleared by the FDA for a Phase 2 trial of a patented drug for delaying aging. Phase 2 trial recruiting begins immediately; efficacy data expected by the end of the first quarter of 2022. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc.

Pharmaceutical

Cannabis Law Report

OCTOBER 6, 2021

Under the terms of this agreement, Sinclair Research will perform preclinical animal studies including method, dosage and toxicity as part of the enabling trials for an Investigational New Drug Application (“IND”) for AnQlar, as required by the U.S. The studies are expected to begin in January of 2022. Forward-Looking Statement.

Research and Development

Cannabis Law Report

NOVEMBER 15, 2021

Finally, we recently acquired the worldwide rights to VRP324, which is an intranasal pharmaceutical-grade cannabidiol product candidate for the management of epilepsy in children (rare pediatric disease) and adults. VRP324 represents our first CNS disorder product indication. On September 9, 2021, Jeffrey A. SCIENTIFIC ACHIEVEMENTS.

Pharmaceutical

Cannabis Law Report

JANUARY 20, 2022

ELE-Psilo program expected to enter clinical trials in Q2 2022 and to target the pressing need for rapid-acting antidepressants compatible with existing healthcare infrastructure and insurance. Eleusis secured an Innovation Passport Designation for ELE-Psilo in adult treatment-resistant depression under the U.K.

Therapy

Cannabis Law Report

JANUARY 5, 2022

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced that the U.S. The patent will be issued on January 11, 2022. The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy.

Pharmaceutical

Veriheal

NOVEMBER 7, 2024

Because the categorization of a controlled substance determines its availability and accessibility, the benefits of rescheduling are important to patients suffering from chronic pain, epilepsy, and other conditions. drug policy and public opinion regarding cannabis’ status as a medicine.

DEA